Affinity Asset Advisors LLC Has $2 Million Position in ESSA Pharma Inc. (NASDAQ:EPIX)

Affinity Asset Advisors LLC cut its position in shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) by 22.2% during the second quarter, Holdings Channel reports. The institutional investor owned 70,000 shares of the company’s stock after selling 20,000 shares during the quarter. Affinity Asset Advisors LLC’s holdings in ESSA Pharma were worth $2,000,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Bellevue Group AG grew its position in ESSA Pharma by 34.7% during the second quarter. Bellevue Group AG now owns 2,459,814 shares of the company’s stock worth $70,277,000 after buying an additional 634,000 shares in the last quarter. Vivo Capital LLC lifted its stake in ESSA Pharma by 9.2% during the first quarter. Vivo Capital LLC now owns 2,068,907 shares of the company’s stock worth $60,102,000 after purchasing an additional 175,000 shares during the period. Janus Henderson Group PLC lifted its stake in ESSA Pharma by 197.8% during the first quarter. Janus Henderson Group PLC now owns 1,516,102 shares of the company’s stock worth $44,032,000 after purchasing an additional 1,007,007 shares during the period. Boxer Capital LLC bought a new position in ESSA Pharma during the first quarter worth about $19,957,000. Finally, Morgan Stanley lifted its stake in ESSA Pharma by 22.8% during the first quarter. Morgan Stanley now owns 572,967 shares of the company’s stock worth $16,644,000 after purchasing an additional 106,253 shares during the period. 84.44% of the stock is currently owned by institutional investors and hedge funds.

Separately, Oppenheimer cut their price target on shares of ESSA Pharma from $36.00 to $22.00 and set an “outperform” rating for the company in a research note on Monday, August 16th. Five investment analysts have rated the stock with a buy rating, Based on data from, the company currently has an average rating of “Buy” and an average price target of $30.25.

Shares of NASDAQ:EPIX traded down $0.15 during trading on Thursday, reaching $8.32. The stock had a trading volume of 701 shares, compared to its average volume of 389,858. The business’s 50-day moving average price is $9.85 and its 200 day moving average price is $21.75. ESSA Pharma Inc. has a 52 week low of $5.40 and a 52 week high of $36.00. The stock has a market capitalization of $336.59 million, a PE ratio of -9.01 and a beta of 1.56.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last posted its quarterly earnings data on Sunday, August 15th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.05. Equities research analysts anticipate that ESSA Pharma Inc. will post -0.99 earnings per share for the current fiscal year.

In other news, major shareholder Growth N. V. Biotech purchased 250,000 shares of the firm’s stock in a transaction dated Wednesday, August 18th. The stock was bought at an average price of $8.88 per share, with a total value of $2,220,000.00. Following the acquisition, the insider now directly owns 5,015,814 shares of the company’s stock, valued at $44,540,428.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 8.00% of the stock is currently owned by insiders.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.

Recommended Story: What is a stock portfolio tracker?

Want to see what other hedge funds are holding EPIX? Visit to get the latest 13F filings and insider trades for ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI).

Institutional Ownership by Quarter for ESSA Pharma (NASDAQ:EPIX)

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.